feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Flight hits Spokane weather balloon

trending

Erie Insurance tornado claim dispute

trending

Tejas fighter jet crashes

trending

Bitcoin price drop warning

trending

Palantir valuation remains too hot

trending

Eli Lilly hits $1 Trillion

trending

Oracle stock slides amid AI concerns

trending

Teacher arrested for child abuse

trending

Amazon recalls children's products

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Brain Pacemaker Offers Hope for Severe Depression

Brain Pacemaker Offers Hope for Severe Depression

18 Nov

•

Summary

  • Brain pacemaker significantly reduced severe depression symptoms in a trial.
  • Over a third of participants achieved remission from depression symptoms.
  • Researchers identified brain activity signature predicting treatment response.
Brain Pacemaker Offers Hope for Severe Depression

A novel brain pacemaker, utilizing deep-brain stimulation (DBS), is offering significant hope for individuals suffering from severe, treatment-resistant depression. A recent study revealed that over a third of participants in a clinical trial achieved remission, experiencing a near-complete elimination of their depressive symptoms. This innovative device functions by delivering controlled electrical signals to specific regions of the brain, effectively regulating errant activity and alleviating the debilitating effects of depression.

The research, conducted by scientists in the UK and China, not only demonstrated the efficacy of DBS but also pinpointed a distinctive brain activity pattern. This 'tell-tale' signature, observed in theta brainwaves within the BNST region, accurately predicted individual patient responses to the treatment. This discovery is a crucial step towards personalized medicine, enabling clinicians to identify and offer this potentially life-changing therapy to those most likely to benefit.

This advancement is particularly significant given the high rates of treatment resistance associated with current depression therapies, which often fail for a substantial portion of patients. The study's findings, published in Nature Communications, suggest that DBS could become a vital tool in managing major depressive disorder, a widespread mental health challenge. The potential for a "closed-loop system" that adjusts stimulation based on real-time brain activity further enhances the promise of this technology for future patient care.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
A brain pacemaker, or deep-brain stimulation (DBS), involves implanting electrodes to send electrical signals to specific brain areas to treat severe depression.
In a recent trial, 34.6% of patients with treatment-resistant depression using DBS achieved remission, with many others showing significant symptom improvement.
Yes, researchers identified a specific theta brainwave activity signature that predicts how well individual patients will respond to DBS treatment.

Read more news on

Healthside-arrow

You may also like

Sea Rise Threatens 5,500 US Hazmat Sites

1 day ago • 5 reads

Your Future Robot Butler Needs You

1 day ago • 6 reads

article image

Beacon & Takeda Turbocharge Narcolepsy Diagnosis

1 day ago • 6 reads

article image

ECT: New Study Demands Suspension Over Heart Risks

20 Nov • 5 reads

article image

AI Watches: Your Personal Health Early Warning System

18 Nov • 9 reads